
FDA Approves Tafasitamab-Cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma
On June 18, 2025, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval of tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL). Tafasitamab-cxix is a monoclonal antibody. Monoclonal…